Literature DB >> 23935557

Optimizing biologic therapy for treatment of inflammatory bowel disease.

Gert Van Assche1.   

Abstract

Entities:  

Year:  2013        PMID: 23935557      PMCID: PMC3736785     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  4 in total

1.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

2.  Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus.

Authors:  Walter Reinisch; Gert Van Assche; Ragnar Befrits; William Connell; Geert D'Haens; Subrata Ghosh; Pierre Michetti; Thomas Ochsenkühn; Remo Panaccione; Stefan Schreiber; Mark S Silverberg; Dario Sorrentino; C Janneke van der Woude; Séverine Vermeire; Julian Panes
Journal:  J Crohns Colitis       Date:  2012-01-10       Impact factor: 9.071

3.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.

Authors:  Paul Rutgeerts; Gert Van Assche; William J Sandborn; Douglas C Wolf; Karel Geboes; Jean-Frédéric Colombel; Walter Reinisch; Ashish Kumar; Andreas Lazar; Anne Camez; Kathleen G Lomax; Paul F Pollack; Geert D'Haens
Journal:  Gastroenterology       Date:  2012-02-08       Impact factor: 22.682

Review 4.  The potential for disease modification in Crohn's disease.

Authors:  G Van Assche; Séverine Vermeire; Paul Rutgeerts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.